Veradigm appoints new CEO
Don Trigg, an alum of primary care and navigation firm Apree Health and EHR vendor Cerner, will take up the role on Sept. 2.
Don Trigg, an alum of primary care and navigation firm Apree Health and EHR vendor Cerner, will take up the role on Sept. 2.
The FDA said the request to quarantine the devices followed reports of the products “resisting shape retention when being bent.”
Medtronic recall of heart vent catheters tied to 3 serious injuries Read More »
The skilled nursing operator filed for bankruptcy in July, a “predictable” outcome after years of financial mismanagement from Genesis’ private equity investors, according to the Private Equity Stakeholder Project.
Private equity owners led to Genesis Healthcare’s bankruptcy: report Read More »
CEO Geoff Martha told investors that the initiatives were done in partnership with the activist investor firm Elliott Investment Management.
Medtronic adds 2 board seats, forms special committees Read More »
The small molecule, vatiquinone, had already flunked a Phase III trial, but the company pushed ahead with an approval bid anyway.
FDA Rejects PTC Therapeutics’ Friedreich’s Ataxia Drug Read More »
A new study in JAMA contradicts a series of statements made by HHS Secretary Robert F. Kennedy Jr. that paint vaccine advisory committees at the CDC and FDA as hopelessly corrupt.
Conflicts of Interest in Vaccine Committees Have Been Plunging for Decades Read More »
The average wage of chief executives rose by 27.5% from 2009 to 2023, while the average pay for all hospital employees rose 9.8%, according to research in Health Affairs.
Pay gap between hospital CEOs and workers on the rise: study Read More »
Viking Therapeutics’ VK2735 achieves a 10.9% placebo-adjusted weight loss at 13 weeks, but a less than ideal safety profile marred the results.
Viking Crashes as Obesity Pill Delivers Over 12% Weight Loss Read More »
Adaptive and Genentech first partnered in 2018 to advance T cell receptor-based therapies for cancer.
Genentech Walks Away From $2B Partnership With Adaptive Biotechnologies Read More »
The FDA has postponed its decision date for Regenxbio’s Hunter syndrome gene therapy to review additional longer-term clinical data for the asset.
Regenxbio’s Hunter Syndrome Gene Therapy Hit With 3-Month PDUFA Delay Read More »